BCTX RSI Chart
Last 7 days
-38.2%
Last 30 days
-35.6%
Last 90 days
-57.0%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2022 | 0 | 0 | 0 | 0 |
2021 | 0 | 0 | 3.1K | 0 |
2020 | 0 | 0 | 0 | 0 |
2019 | 0 | 0 | 12.0K | 0 |
2018 | 0 | 0 | 16.0K | 0 |
Which funds bought or sold BCTX recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | MORGAN STANLEY | reduced | -63.48 | -311,407 | 67,679 | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | added | 1.12 | -52,647 | 51,477 | -% |
May 15, 2024 | Atom Investors LP | sold off | -100 | -64,186 | - | -% |
May 15, 2024 | CITADEL ADVISORS LLC | reduced | -57.02 | -69,094 | 18,381 | -% |
May 15, 2024 | Royal Bank of Canada | reduced | -80.65 | -99,000 | 10,000 | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | added | 49.05 | -838 | 2,251 | -% |
May 15, 2024 | SABBY MANAGEMENT, LLC | new | - | 97,875,000 | 97,875,000 | 0.06% |
May 15, 2024 | ARMISTICE CAPITAL, LLC | unchanged | - | -427,500 | 510,000 | 0.01% |
May 13, 2024 | NATIXIS | sold off | -100 | -130,344 | - | -% |
May 13, 2024 | NATIONAL BANK OF CANADA /FI/ | unchanged | - | -23,250 | 16,725 | -% |
BriaCell Therapeutics Corp. News
Income Statement (Quarterly) | ||||||||||||||
Description | (%) Q/Q | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2018Q3 |
Revenue | 197.9% | 36.00 | 12.00 | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses | 13.1% | 4,123 | 3,647 | 2,285 | 1,596 | 4,807 | 190 | - | - | - | 1,879 | - | - | - |
S&GA Expenses | -4.3% | 1,854 | 1,939 | 1,409 | 1,018 | 3,681 | 25.00 | - | - | - | 663 | - | - | - |
R&D Expenses | 32.8% | 2,269 | 1,708 | 876 | 581 | 1,125 | 166 | - | - | - | 1,216 | - | - | - |
Interest Expenses | - | - | - | 979* | -45.37 | 62.00 | 46.00 | - | - | - | 639* | - | - | - |
Net Income | -189.7% | -10,015 | 11,161 | -27,533 | -2,720 | 2,950 | -235 | - | - | - | -1,882 | - | - | - |
Net Income Margin | -80.3% | -9.24 | -5.13 | -8.75 | -4.39 | -411.88* | -411.88* | -411.88* | -411.88* | -392.60* | -392.60* | -392.60* | - | - |
Free Cashflow | -88.7% | -4,823 | -2,556 | -1,778 | -1,945 | -5,587 | - | - | - | - | - | - | - | - |
Balance Sheet | |||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2019Q3 |
Assets | -34.3% | 12,231 | 18,619 | 27,164 | 29,722 | 34,161 | 38,450 | 42,577 | 46,461 | 48,554 | 53,299 | 58,044 | 46,524 | 35,004 | 23,484 | 11,964 | 445 |
Current Assets | -36.2% | 11,742 | 18,408 | 26,949 | 29,503 | 33,939 | 38,224 | 42,347 | 46,227 | 48,316 | - | 57,798 | - | 274 | - | 261 | 169 |
Cash Equivalents | -54.2% | 6,245 | 13,646 | 21,251 | 28,170 | 33,500 | 37,452 | 41,042 | 44,527 | 47,982 | - | 57,269 | 20,064 | 6.00 | - | 21.00 | 157 |
Current Liabilities | 275.0% | 3,924 | 1,047 | 1,801 | 1,383 | 670 | 974 | 941 | 366 | 605 | - | 557 | - | 4,919 | - | 3,964 | 1,392 |
Shareholder's Equity | -430.5% | -8,317 | 2,516 | -3,777 | - | -1,280 | 10,334 | 10,329 | 9,958 | 16,426 | 1,584 | 27,672 | 14,485 | - | - | - | - |
Retained Earnings | -15.1% | -85,945 | -74,650 | -80,652 | -78,233 | -73,338 | -61,456 | -60,349 | -27,582 | -22,758 | - | -29,141 | - | -23,028 | - | -22,326 | -14,746 |
Additional Paid-In Capital | -100.0% | - | 7,919 | 7,422 | 6,888 | 6,607 | 6,340 | 5,228 | - | - | - | 2,178 | - | - | - | - | - |
Shares Outstanding | 0% | 15,982 | 15,982 | 15,982 | 15,518 | 15,518 | 15,518 | 15,518 | 15,359 | 15,547 | 15,239 | 15,270 | - | - | - | - | - |
Minority Interest | -19.2% | -244 | -205 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cashflow (Quarterly) | |||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2018Q3 |
Cashflow From Operations | 2.7% | -7,401 | -7,605 | -10,919 | -5,331 | -3,951 | -3,542 | -3,325 | -4,823 | -2,556 | -1,778 | -1,945 | -5,587 | - | - | - | - | - | - | - | - |
Share Based Compensation | -6.3% | 500 | 534 | 534 | 281 | 267 | 1,112 | 878 | 864 | 815 | 518 | - | - | - | - | - | - | - | - | - | - |
Cashflow From Financing | - | - | - | 4,000 | 2.00 | - | -47.29 | -159 | 1,369 | - | - | 38,294 | 26,462 | - | - | - | - | - | - | - | - |
Buy Backs | - | - | - | - | - | - | 47.00 | - | - | 9,098 | - | - | - | - | - | - | - | - | - | - | - |
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) | 3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jan. 31, 2024 | Jan. 31, 2023 | Jan. 31, 2024 | Jan. 31, 2023 | |
Operating Expenses: | ||||
Research and development expenses | $ 8,257,455 | $ 3,053,357 | $ 15,114,712 | $ 6,308,572 |
General and administrative expenses | 1,571,991 | 1,432,966 | 3,217,762 | 3,580,902 |
Total operating expenses | 9,829,446 | 4,486,323 | 18,332,474 | 9,889,474 |
Operating loss | (9,829,446) | (4,486,323) | (18,332,474) | (9,889,474) |
Financial expenses, net | (1,486,119) | (7,395,439) | 12,975,781 | (3,098,829) |
Share of loss on equity investment | (18,345) | (18,345) | ||
Net loss for the period | (11,333,910) | (11,881,762) | (5,375,038) | (12,988,303) |
Net loss attributable to non-controlling interest | (39,307) | (81,978) | ||
Net loss and Comprehensive loss for the period attributable to BriaCell | $ (11,294,603) | $ (11,881,762) | $ (5,293,060) | $ (12,988,303) |
Net loss per share attributable to BriaCell - basic | $ (0.71) | $ (0.77) | $ (0.33) | $ (0.84) |
Net loss per share attributable to BriaCell - diluted | $ (0.71) | $ (0.77) | $ (0.33) | $ (0.84) |
Weighted average number of shares used in computing net basic earnings per share of common stock | 15,981,726 | 15,518,018 | 15,981,726 | 15,518,018 |
Weighted average number of shares used in computing net diluted earnings per share of common stock | 15,981,726 | 15,518,018 | 15,981,726 | 15,518,018 |
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) | Jan. 31, 2024 | Jul. 31, 2023 |
---|---|---|
CURRENT ASSETS: | ||
Cash and cash equivalents | $ 6,244,528 | $ 21,251,092 |
Amounts receivable | 30,145 | 18,873 |
Prepaid expenses | 5,467,286 | 5,678,542 |
Total current assets | 11,741,959 | 26,948,507 |
NON-CURRENT ASSETS: | ||
Investments | 2 | 2 |
Equity investment in BC Therapeutics | 281,655 | |
Intangible assets, net | 207,431 | 215,068 |
Total non-current assets | 489,088 | 215,070 |
Total assets | 12,231,047 | 27,163,577 |
CURRENT LIABILITIES: | ||
Trade payables | 3,711,455 | 1,123,739 |
Accrued expenses and other payables | 212,870 | 677,718 |
Total current liabilities | 3,924,325 | 1,801,457 |
NON-CURRENT LIABILITIES: | ||
Warrant liability | 16,624,177 | 29,139,301 |
Total non-current liabilities | 16,624,177 | 29,139,301 |
SHAREHOLDERS’ DEFICIT: | ||
Share Capital of no par value - Authorized: unlimited at January 31, 2024 and July 31, 2023, Issued and outstanding: 15,981,726 shares January 31, 2024 and July 31, 2023, respectively | 69,591,784 | 69,591,784 |
Share-based payment reserve | 8,419,154 | 7,421,950 |
Accumulated other comprehensive loss | (138,684) | (138,684) |
Non-controlling Interest | (244,418) | |
Accumulated deficit | (85,945,291) | (80,652,231) |
Total shareholders’ deficit | (8,317,455) | (3,777,181) |
Total liabilities and shareholders’ deficit | $ 12,231,047 | $ 27,163,577 |